TimesSquare Capital Management LLC Purchases Shares of 157,327 Kymera Therapeutics, Inc. $KYMR

TimesSquare Capital Management LLC purchased a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 157,327 shares of the company’s stock, valued at approximately $18,041,000. TimesSquare Capital Management LLC owned about 0.19% of Kymera Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in the business. Smartleaf Asset Management LLC boosted its stake in Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares during the period. Larson Financial Group LLC grew its holdings in Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after buying an additional 349 shares during the last quarter. Osaic Holdings Inc. increased its position in Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares during the period. GAMMA Investing LLC increased its position in Kymera Therapeutics by 27.5% in the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after buying an additional 98 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Kymera Therapeutics during the fourth quarter worth approximately $63,000.

Insider Buying and Selling at Kymera Therapeutics

In other news, Director Bruce Booth sold 467,878 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $110.29, for a total value of $51,602,264.62. Following the sale, the director directly owned 472,267 shares in the company, valued at approximately $52,086,327.43. This represents a 49.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Bruce N. Jacobs sold 77,109 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $114.96, for a total value of $8,864,450.64. Following the completion of the transaction, the chief financial officer directly owned 244,883 shares of the company’s stock, valued at approximately $28,151,749.68. The trade was a 23.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,604,813 shares of company stock worth $387,557,004 in the last three months. 15.98% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on KYMR shares. B. Riley Financial increased their price objective on Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Morgan Stanley reaffirmed an “overweight” rating and set a $135.00 target price on shares of Kymera Therapeutics in a research report on Thursday, August 6th. Truist Financial upped their target price on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Mizuho increased their price target on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a report on Thursday, July 16th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Kymera Therapeutics in a research report on Thursday, July 30th. They issued a “hold” rating and a $120.00 price target on the stock. Twenty analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $125.65.

Kymera Therapeutics Stock Performance

Shares of KYMR stock opened at $121.41 on Tuesday. Kymera Therapeutics, Inc. has a 52-week low of $39.84 and a 52-week high of $130.05. The stock has a market cap of $10.10 billion, a price-to-earnings ratio of -37.47 and a beta of 1.95. The firm has a fifty day moving average of $106.11 and a 200-day moving average of $90.76.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.09. The company had revenue of $65.00 million during the quarter, compared to the consensus estimate of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The firm’s revenue for the quarter was up 465.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.95) EPS. On average, sell-side analysts predict that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.